Press

CTAD Lessons for 2020: More Phase 2 Trials, More Diversity

Alzforum

-Funding agencies encourage exploration of more diverse therapeutic targets. -A return to getting efficacy data in Phase 2 may lower failure rate in Phase 3. -Machine learning could help slim down and streamline trials.